These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 26077004)

  • 21. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
    Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
    Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
    Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
    BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.
    Chin LJ; Ratner E; Leng S; Zhai R; Nallur S; Babar I; Muller RU; Straka E; Su L; Burki EA; Crowell RE; Patel R; Kulkarni T; Homer R; Zelterman D; Kidd KK; Zhu Y; Christiani DC; Belinsky SA; Slack FJ; Weidhaas JB
    Cancer Res; 2008 Oct; 68(20):8535-40. PubMed ID: 18922928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.
    Jiang L; Huang J; Morehouse C; Zhu W; Korolevich S; Sui D; Ge X; Lehmann K; Liu Z; Kiefer C; Czapiga M; Su X; Brohawn P; Gu Y; Higgs BW; Yao Y
    Cancer Genet; 2013; 206(9-10):330-9. PubMed ID: 24200637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients.
    Bhaumik S; Ahmad F; Das BR
    Med Oncol; 2016 Oct; 33(10):117. PubMed ID: 27637917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer.
    Nelson HH; Christensen BC; Plaza SL; Wiencke JK; Marsit CJ; Kelsey KT
    Lung Cancer; 2010 Jul; 69(1):51-3. PubMed ID: 19854534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients.
    Villalva C; Duranton-Tanneur V; Guilloteau K; Burel-Vandenbos F; Wager M; Doyen J; Levillain PM; Fontaine D; Blons H; Pedeutour F; Karayan-Tapon L
    Cancer Med; 2013 Jun; 2(3):296-304. PubMed ID: 23930206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer.
    Marchoudi N; Amrani Hassani Joutei H; Jouali F; Fekkak J; Rhaissi H
    Pathol Biol (Paris); 2013 Dec; 61(6):273-6. PubMed ID: 23849768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma.
    Adackapara CA; Sholl LM; Barletta JA; Hornick JL
    Histopathology; 2013 Aug; 63(2):187-93. PubMed ID: 23763264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The proto-oncogene KRAS and BRAF profiles and some clinical characteristics in colorectal cancer in the Turkish population.
    Ozen F; Ozdemir S; Zemheri E; Hacimuto G; Silan F; Ozdemir O
    Genet Test Mol Biomarkers; 2013 Feb; 17(2):135-9. PubMed ID: 23297805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer.
    Tomasini P; Serdjebi C; Khobta N; Metellus P; Ouafik L; Nanni I; Greillier L; Loundou A; Fina F; Mascaux C; Barlesi F
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer.
    Nicoś M; Krawczyk P; Jarosz B; Sawicki M; Szumiłło J; Trojanowski T; Milanowski J
    Clin Exp Med; 2016 May; 16(2):169-76. PubMed ID: 25902737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients.
    Manoharan V; Karunanayake EH; Tennekoon KH; De Silva S; Imthikab AIA; De Silva K; Angunawela P; Vishwakula S; Lunec J
    BMC Cancer; 2020 Jan; 20(1):72. PubMed ID: 32000721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [BRAF gene mutation in wild-type KRAS patients with colorectal cancers].
    Roa I; Game A; Bizama C; Schalper K
    Rev Med Chil; 2014 Jan; 142(1):55-60. PubMed ID: 24861115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
    Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
    Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma.
    Pang NK; Nga ME; Chin SY; Ismail TM; Lim GL; Soong R; Salto-Tellez M
    Cytopathology; 2011 Dec; 22(6):358-64. PubMed ID: 21029218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the Role of the KRAS Gene Polymorphism LCS6 (rs61764370) in Iraqi Women with Ovarian Cancer.
    Ghazi Jumaa M
    Arch Razi Inst; 2022 Feb; 77(1):205-211. PubMed ID: 35891756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases].
    Gao J; Sun ZW; Li YY; Shen L
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):579-83. PubMed ID: 23157823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.